Pharmceutical composition for treatment of wounds conntaining blood plasma or serum

Abstract

The present invention relates to a pharmaceutical composition for the treatment of wounds containing blood plasma or serum and a method for treating wounds effectively by applying said composition to the wound site to normalize the tissue-environment around the site.

1 . A pharmaceutical composition for the treatment of wounds, comprising a pharmaceutically effective amount of blood plasma as an active agent.  
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein pH is in the range of 3.5 to 6.6  
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein the active agent is derived from livestock.  
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein it is topically administered.  
     
     
         5 . The pharmaceutical composition according to  claim 1 , in the form of creams, ointments, gels, liquids or patched.  
     
     
         6 . The pharmaceutical composition according to  claim 1 , wherein the wounds include contusion or bruise, non-healing traumatic wounds, the disruption by irradiation, abrasion, bone gangrene, laceration, avulsion, penetrated wound, gun shot wound, cutting, burn, cold sores, cutaneous ulcers, xeroderma, skin kefatosis, break, rupture, dermatitis, pain by dermatophyte, wounds by surgery or by vascular disorder, corneal wounds, pressure sore, bed sore, certain conditions associated with diabetes such as diabetic cutaneous disorder and with poor circulation, chronic ulcers, suture site caused by plastic surgery, spinal traumatic wounds, gynecological wounds, chemical wounds and acne.  
     
     
         7 . The pharmaceutical composition according to  claim 1 , which is used at an amount of from 0.01 to 0.1 g/cm 2  in the treatment of full thickness defect wounds.  
     
     
         8 . A pharmaceutical composition for the treatment of wounds, comprising a pharmaceutically effective amount of blood serum as an active agent.  
     
     
         9 . The pharmaceutical composition according to  claim 8 , wherein pH is in the range of 3.5 to 6.6  
     
     
         10 . The pharmaceutical composition according to  claim 8 , wherein the active agent is derived from livestock.  
     
     
         11 . The pharmaceutical composition according to  claim 8 , wherein it is topically administered.  
     
     
         12 . The pharmaceutical composition according to  claim 8 , in the form of creams, ointments, gels, liquids or patched.  
     
     
         13 . The pharmaceutical composition according to  claim 8 , wherein the wounds include contusion or bruise, non-healing traumatic wounds, the disruption by irradiation, abrasion, bone gangrene, laceration, avulsion, penetrated wound, gun shot wound, cutting, burn, cold sores, cutaneous ulcers, xeroderma, skin kefatosis, break, rupture, dermatitis, pain by dermatophyte, wounds by surgery or by vascular disorder, corneal wounds, pressure sore, bed sore, certain conditions associated with diabetes such as diabetic cutaneous disorder and with poor circulation, chronic ulcers, suture site caused by plastic surgery, spinal traumatic wounds, gynecological wounds, chemical wounds and acne.  
     
     
         14 . The pharmaceutical composition according to  claim 8 , which is used at an amount of from 0.01 to 0.1 g/cm 2  in the treatment of full thickness defect wounds.  
     
     
         15 . The pharmaceutical composition according to  claim 6 , which is used at an amount of from 0.01 to 0.1 g/cm 2  in the treatment of full thickness defect wounds.  
     
     
         16 . The pharmaceutical composition according to  claim 13 , which is used at an amount of from 0.01 to 0.1 g/cm 2  in the treatment of full thickness defect wounds.